Similar articles

• High-risk acute lymphoblastic leukemia (ALL): is there an alternative approach for increasing the number of cures?

  Carella AM. Carella AM. Haematologica. 1992 Jul-Aug;77(4):348-51. Haematologica. 1992. PMID: 1358772 Review. No abstract available.
• Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.

  Deliliers GL, Annaloro C, Oriani A, Della Volpe A, Boschetti C, Cortelezzi A, Maiolo AT. Deliliers GL, et al. Ann Ital Med Int. 1998 Jul-Sep;13(3):146-51. Ann Ital Med Int. 1998. PMID: 9859570 Clinical Trial.
• Therapy of adult ALL: overview of 2 successive EORTC studies: (ALL-2 & ALL-3). The EORTC Leukemia Cooperative Study Group.

  Stryckmans P, De Witte T, Marie JP, Fillet G, Peetermans M, Bury J, Muus P, Andrien JM, Hayat M, Jaksic B, et al. Stryckmans P, et al. Leukemia. 1992;6 Suppl 2:199-203. Leukemia. 1992. PMID: 1578934 Clinical Trial. No abstract available.
• Allogeneic versus autologous bone marrow transplantation versus intensive post-remission chemotherapy in acute leukaemias.

  Bernasconi C, Lazzarino M, Canevari A, Morra E, Castelli G, Brusamolino E, Alessandrino EP, Pagnucco G, Orlandi E, Castagnola C, et al. Bernasconi C, et al. Bone Marrow Transplant. 1989 Dec;4 Suppl 4:65-8. Bone Marrow Transplant. 1989. PMID: 2697439 Review. No abstract available.
• A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.

  Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F. Testi AM, et al. Haematologica. 1997 Nov-Dec;82(6):664-7. Haematologica. 1997. PMID: 9499665 Clinical Trial.